| # | Title | Journal | Year | Citations |
|---|
| 1 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Lancet, The | 2012 | 2,691 |
| 2 | European Society of Contact Dermatitis guideline for diagnostic patch testing – recommendations on best practice | Contact Dermatitis | 2015 | 1,012 |
| 3 | Myocarditis in Patients Treated With Immune Checkpoint Inhibitors | Journal of the American College of Cardiology | 2018 | 997 |
| 4 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) | European Journal of Immunology | 2019 | 766 |
| 5 | The skin prick test – European standards | Clinical and Translational Allergy | 2013 | 562 |
| 6 | Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy | European Journal of Cancer | 2016 | 546 |
| 7 | The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Nature Medicine | 2008 | 535 |
| 8 | Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy | European Journal of Cancer | 2016 | 490 |
| 9 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab | Clinical Cancer Research | 2016 | 480 |
| 10 | The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network | PLoS ONE | 2013 | 414 |
| 11 | Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG | Annals of Oncology | 2006 | 400 |
| 12 | Towards quality management of medical information on the internet: evaluation, labelling, and filtering of information | BMJ: British Medical Journal | 1998 | 363 |
| 13 | Hypoxia and Hypoxia-Inducible Factor-1α Modulate Lipopolysaccharide-Induced Dendritic Cell Activation and Function | Journal of Immunology | 2008 | 363 |
| 14 | Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo | Nature Genetics | 2012 | 293 |
| 15 | Immobilized Chemokine Fields and Soluble Chemokine Gradients Cooperatively Shape Migration Patterns of Dendritic Cells | Immunity | 2010 | 282 |
| 16 | Myocarditis in the Setting of Cancer Therapeutics | Circulation | 2019 | 278 |
| 17 | Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease | Nature Immunology | 2017 | 274 |
| 18 | DC-SIGN and CLEC-2 Mediate Human Immunodeficiency Virus Type 1 Capture by Platelets | Journal of Virology | 2006 | 234 |
| 19 | Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants | Nature Genetics | 2016 | 225 |
| 20 | Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development | European Journal of Immunology | 2009 | 217 |
| 21 | Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis | European Heart Journal | 2020 | 212 |
| 22 | Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins | Clinical Cancer Research | 2014 | 200 |
| 23 | Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis | Journal of the American College of Cardiology | 2020 | 179 |
| 24 | Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors | European Journal of Cancer | 2019 | 171 |
| 25 | Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity | European Journal of Cancer | 2017 | 162 |
| 26 | Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition | European Journal of Cancer | 2017 | 162 |
| 27 | Subsets, expansion and activation of myeloid-derived suppressor cells | Medical Microbiology and Immunology | 2010 | 150 |
| 28 | Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment | Science Immunology | 2016 | 145 |
| 29 | Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma | European Journal of Cancer | 2017 | 145 |
| 30 | Patch test results of the European baseline series among patients with occupational contact dermatitis across Europe – analyses of the European Surveillance System on Contact Allergy network, 2002–2010 | Contact Dermatitis | 2015 | 144 |
| 31 | Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis | Circulation | 2020 | 142 |
| 32 | Exosomes from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells License Quiescent CD4 + T Lymphocytes To Replicate HIV-1 through a Nef- and ADAM17-Dependent Mechanism | Journal of Virology | 2014 | 140 |
| 33 | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 | Journal of Experimental Medicine | 2004 | 133 |
| 34 | CD83: an update on functions and prospects of the maturation marker of dendritic cells | Archives of Dermatological Research | 2007 | 127 |
| 35 | Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma | Cancer | 2000 | 126 |
| 36 | Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts | European Journal of Cancer | 2021 | 115 |
| 37 | Targeting of DEC-205 on human dendritic cells results in efficient MHC class II–restricted antigen presentation | Blood | 2010 | 111 |
| 38 | CLEC10A Is a Specific Marker for Human CD1c+ Dendritic Cells and Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion | Frontiers in Immunology | 2018 | 110 |
| 39 | CD83 Knockdown in Monocyte-Derived Dendritic Cells by Small Interfering RNA Leads to a Diminished T Cell Stimulation | Journal of Immunology | 2007 | 109 |
| 40 | Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study | | 2019 | 108 |
| 41 | European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14 | Journal of the European Academy of Dermatology and Venereology | 2017 | 106 |
| 42 | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | Gene Therapy | 2009 | 105 |
| 43 | Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy | Immunotherapy | 2017 | 104 |
| 44 | Biogenesis and Functions of Exosomes and Extracellular Vesicles | Methods in Molecular Biology | 2016 | 102 |
| 45 | Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients | Annals of Oncology | 2015 | 101 |
| 46 | Dendritic cells in cancer immunotherapy | European Journal of Immunology | 2010 | 100 |
| 47 | Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis | Journal of the American College of Cardiology | 2021 | 97 |
| 48 | H1‐antihistamine‐refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter real‐life AWARE study | Clinical and Experimental Allergy | 2017 | 96 |
| 49 | Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders | Cancer Immunology, Immunotherapy | 2018 | 91 |
| 50 | Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations | British Journal of Cancer | 2013 | 88 |
